Prospectus
Filed with ASX · · 48 pages · English
Summary by 6ix AI
Adherium Ltd. has filed a prospectus for an accelerated non-renounceable entitlement offer to eligible shareholders, allowing them to purchase new shares and options at a specified price. The offer aims to raise a maximum amount before costs, with details on the rights and liabilities attached to the new shares and options included in the document. The prospectus outlines important dates and actions required by eligible retail shareholders to participate in the offer. Investors are advised to read the entire prospectus carefully, as it contains risk factors and other critical information regarding the investment.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
On 6ix: 6ix.com/news/prospectus-132
Story so far
Earlier from Adherium
- Accel Non-Renounceable Entitlement Offer to raise up to $4m
- $900K Capital Raise to Accelerate Smart Inhaler in US
- Adherium Secures $2.6M to Advance Smart Inhaler in US
- Management Change
- AstraZeneca selected Adherium Smartinhaler for its study
Later from Adherium
- Successful Completion of Institutional Component of ANREO
- Replacement Prospectus
- Successful Completion of Retail Component of ANREO
- Adherium Appoints Dawn Bitz as CEO
- Firm commitments received for institutional placement
Follow Adherium into a list and get an email when it puts out news.
Follow Adherium